Raman spectroscopy’s ability to distinguish AD tissues from normal tissues relies on recognizing AD-specific molecular shifts, including the accumulation of Aβ fibrils, tau fibrils, and other metabolic changes. This evidence concerns the gene MAPT and Alzheimer disease.